Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort - Université Claude Bernard Lyon 1 Accéder directement au contenu
Article Dans Une Revue Clinics and Research in Hepatology and Gastroenterology Année : 2020

Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort

Anais Vallet-Pichard
  • Fonction : Auteur
Jean-Michel Correas
  • Fonction : Auteur
Celine Dorival
  • Fonction : Auteur
Albert Tran
  • Fonction : Auteur
Marc Bourlière
  • Fonction : Auteur
Paul Calès
Dominique Guyader
  • Fonction : Auteur
Jean-Pierre Bronowicki
  • Fonction : Auteur
Dominique Larrey
Christophe Hezode
  • Fonction : Auteur
Veronique Loustaud-Ratti
  • Fonction : Auteur
Jerome Gournay
  • Fonction : Auteur
Victor de Ledinghen
Tarik Asselah
  • Fonction : Auteur
Nathalie Ganne
  • Fonction : Auteur
Sophie Metivier
  • Fonction : Auteur
Olivier Chazouillères
  • Fonction : Auteur
Leroy Vincent
  • Fonction : Auteur
Isabelle Rosa
  • Fonction : Auteur
Didier Samuel
  • Fonction : Auteur
Carole Cagnot
Helene Fontaine
  • Fonction : Auteur
Stanislas Pol
Thomas F. Baumert
Michel Doffoel
  • Fonction : Auteur
  • PersonId : 1062946

Résumé

BACKGROUND: Although it has now been excluded that direct-acting antivirals (DAA) are associated with a significant risk of hepatocellular carcinoma (HCC) in HCV-infected patients, a possible effect of DAA on tumor growth is still a subject of debate. We performed a blind comparison of the kinetics of HCC recurrence in patients after HCV treatment with or without DAA to evaluate the potential aggressiveness of HCC after DAA treatment. BASIC PROCEDURES: Thirty-nine HCV-infected patients from the AFEF/ANRS CO22 Hepather cohort who experienced HCC recurrence after so-called curative treatment were evaluated. Contrast-enhanced CT and/or MR images were read blindly 6 months before HCC recurrence and during the follow-up period. Seventeen patients who received DAA (DAA+) before HCC recurrence were compared to the 22 who did not receive (DAA-), according to the LiRads and mRECIST criteria. MAIN FINDINGS: There were 28 men and 11 women, median age 62 years old, 37 (95%) with cirrhosis. DAA+ patients had a lower median MELD score (8±2 vs. 10±4, P=0.0286) than DAA- patients. The median time to HCC recurrence (time from the date of curative treatment to the diagnosis of recurrence) was not different (20 vs. 18 months) (P=0.73) between the two groups. There was no difference between the 2 groups in the overall survival and/or transplantation-free survival (P=0.71) and for the mRECIST time to progression (P=0.25). CONCLUSION: This blinded analysis of HCC recurrence after HCC treatment does not support any negative impact of DAA therapy on the severity or progression of recurrent HCC.
Fichier principal
Vignette du fichier
S2210740120301522.pdf (871.69 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02921184 , version 1 (03-02-2023)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Anais Vallet-Pichard, Jean-Michel Correas, Celine Dorival, Fabien Zoulim, Albert Tran, et al.. Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. Clinics and Research in Hepatology and Gastroenterology, 2020, ⟨10.1016/j.clinre.2020.04.022⟩. ⟨hal-02921184⟩
51 Consultations
9 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More